IMDX

Insight Molecular Diagnostics Inc.

Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. CA· CIK 0001642380 Biotech & Drug Discovery

$3.00 +0.17 (+6.01%)

Oct 26 4:00 PM ET · prev $2.83

Market cap

$92.9M

Micro cap

Consensus

Buy

73% Buy or better · 11 analysts

Median target

$8.50

+183% · range $4.00–12.00

Next earnings

Nov 5

in 10 days · EPS est. −$0.22

1 year

−53.8%

from $6.50 · Oct 27

30 days

−5.7%

from $3.18

52-week range

$2.55–8.48

−65% from high · low Mar 30

Avg volume 20D

282.8K

shares / day

Short interest

🔒 Subscribers only

Insider net

+$5.7M

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Reddit crowd

60°

Warm · 1 mention this week

SecBot read MIXED 1 report · 90 days

Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score

Avg score

·Next Earnings date, Nov 5, 2026

Strongest NEUTRAL IMDX reported Q2 2026 revenue of $239K (GAAP net loss -$0.31/share), essentially pre-revenue as it awaits…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Feb 10 1 insider buy $3.0M at $5.75
R Mar 26 Insight Molecular Diagnostics (IMDX) reported strong revenue growth…
B Apr 16 to Apr 27 6 days of insider buys: $2.7M by 1 insider, avg $3.57
R Aug 10 IMDX reported Q2 2026 revenue of $239K (GAAP net loss -$0.31/share),…
A Aug 24 LUCID CAPITAL MARKETS initiates

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $5.7M at an average $4.46. No open-market sales. Price is 33% below their cost.
InstitutionsBULLISH

Q2 2026: 5 added (0 new), 0 trimmed or exited.
AnalystsBULLISH

8 of 11 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate −$0.180 → −$0.220 over 90 days. 0 up, 1 down in 30 days.
TrendDOWNTREND

19% below its 50-day average.
SocialQUIET

Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	ADD	735,847	$4.3M
STATE STREET CORP	ADD	92,124	$543.5K
UBS Group AG	DOUBLED	53,276	$314.3K
OSAIC HOLDINGS, INC.	ADD	39,136	$230.9K
BNP PARIBAS FINANCIAL MARKETS	DOUBLED	5,801	$34.2K
MILLENNIUM MANAGEMENT LLC	ADD	103,470	$339.4K
UBS Group AG	DOUBLED	22,751	$74.6K
OMERS ADMINISTRATION Corp	TRIM	10,500	$34.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts

Buy 73% rate it Buy or better

Strong Buy2Buy6Hold3Sell0Strong Sell0

12-month targets · 4 analysts

$3.00 $4.00 $8.50 $12.00

Price is below the lowest target. Median implies +183%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 24, 2026	LUCID CAPITAL MARKETS INITIATE	INITIATE	Buy
Aug 18, 2026	Needham REITERATE	REITERATE	Buy

Crowd this week 60° Warm 1 bullish · 0 bearish

Mentions, 7 days 1 0 in posts · 1 in comments

Insider ledger

Form 4

$5.7M

bought · 1 insider

sold · 0 insiders

−32.7%

vs their $4.46 cost

Date	Insider	Type	Value
Jul 1, 2026	Arno Andrew Director	TAX W/H	$68.8K
Jul 1, 2026	SILVERMAN LOU Director	TAX W/H	$43.8K
Jul 1, 2026	Last Andrew J. Director	TAX W/H	$43.8K
Jun 11, 2026	SILVERMAN LOU Director	AWARD	26,943 sh
Jun 11, 2026	Arno Andrew Director	AWARD	32,331 sh
Jun 11, 2026	Last Andrew J. Director	AWARD	26,943 sh
Apr 27, 2026	BROADWOOD PARTNERS, L.P. 10%+ Owner	BUY	$913.1K
Apr 27, 2026	BROADWOOD PARTNERS, L.P. 10%+ Owner	BUY	0 sh

Earnings setup

Estimates

Nov 5

reports in 10 days

−$0.22

EPS estimate, this quarter

−22%

estimate change, 90 days

0↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.180

90d

−$0.200

60d

−$0.220

30d

−$0.220

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.22	-$0.24–-$0.20	+0.0%	$244.3K
Next Q	-$0.23	-$0.24–-$0.22	+0.0%	$473.7K
Current FY	-$0.93	-$0.93–-$0.92	+0.0%	$966.2K
Next FY	-$0.80	-$0.84–-$0.76	+0.0%	$6.7M